An2 Therapeutics, INC. (ANTX) — 10-Q Filings

All 10-Q filings from An2 Therapeutics, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

ANTX Narrows Q3 Loss, R&D Spend Halved Amid Cash Burn — Nov 12, 2025 Risk: medium
AN2 Therapeutics, Inc. (ANTX) reported a net loss of $9.353 million for the three months ended September 30, 2025, an improvement from a net loss of $12.747 mil
ANTX Narrows Losses Amid Sharp R&D Spending Cut — Aug 12, 2025 Risk: medium
AN2 Therapeutics, Inc. (ANTX) reported a net loss of $6.46 million for the three months ended June 30, 2025, a significant improvement from the $14.44 million n
AN2 Therapeutics Files Q1 2025 10-Q — May 13, 2025 Risk: medium
AN2 Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus remains on its pharmaceutical preparations business. Key
AN2 Therapeutics Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
AN2 Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financial
AN2 Therapeutics Q2 2024 Update — Aug 13, 2024 Risk: medium
AN2 Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial condition and results of operations, including

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX